• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

clscott@unimelb.edu.au

Credentials


Position
Professor of Gynaecological Cancer
Department of Obstetrics, Gynaecology and Newborn Health
Education
PhD
University of Melbourne
Bachelors Degree
University of Melbourne
ORCID

0000-0002-3689-5956

Prof Clare Scott

Professor of Gynaecological Cancer
Department of Obstetrics, Gynaecology and Newborn Health

625 Scholarly works
5 Projects

HIGHLIGHTS

  • 2024

    Journal article

    BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance
    DOI: 10.1186/s12943-024-02048-1
  • 2022

    Research Contracts

    Salary Contribution Ci Clare Scott 22/23
  • 2020

    Research Grant

    A Multiple Modality Approach for Targeting Chemotherapy-and Parpi-Resisatnt Ovarian Cancer
  • 2018

    Journal article

    Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
    DOI: 10.1038/s41467-018-05564-z
  • 2017

    Journal article

    Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma
    DOI: 10.1158/2159-8290.CD-17-0419
  • 2017

    Research Grant

    Stics and Stones: A Randomised Phase Ii Double-Blind Placebo-Controlled Trial of Acetylsalicylic Acid (Asa) in Chemoprevention of Ovarian Cancer in Women With Brca1 and Brca2 Mutations
  • 2016

    Conference Proceedings

    Secondary mutations in RAD51C and RAD51D are associated with acquired resistance to the PARP inhibitor rucaparib in patients with high-grade ovarian cancer
    DOI: 10.1016/S0959-8049(16)32627-2
Clare Scott

RECENT SCHOLARLY WORKS

  • 2026

    Journal article

    High-throughput drug screening identifies EGFR/MAPK pathway targeting sensitivities in organoid models of ovarian carcinosarcoma
    DOI: 10.1186/s13046-025-03629-8
  • 2026

    Journal article

    Ovarian cancer
    DOI: 10.1038/s41572-026-00686-x
  • 2026

    Journal article

    Uterine leiomyosarcoma: independent prognostic factors for overall and recurrence-free survival in a large international cohort
    DOI: 10.1016/j.ijgc.2025.103167
  • 2026

    Journal article

    Quality Matters: Linking Patterns of Care to Ovarian Cancer Survival in a National Gynae-Oncology Registry.
    DOI: 10.1200/OP-25-00664
  • 2025

    Journal article

    768P Operational challenges of molecular tumour board (MTBs) in the Australasian public healthcare services: A scoping survey to inform the future of precision oncology
    DOI: 10.1016/j.annonc.2025.10.1183
  • 2025

    Journal article

    EXPRESSION OF EMERGING THERAPEUTIC TARGET B7-H3 IN SARCOMA - A MASS SPECTROMETRY-BASED PROTEOMIC ANALYSIS OF >1000 SARCOMA SAMPLES
    DOI: 10.1016/j.esmorc.2025.100050
  • 2025

    Journal article

    HCMV as an Oncomodulatory Virus in Ovarian Cancer: Implications of Viral Strain Heterogeneity, Immunomodulation, and Inflammation on the Tumour Microenvironment and Ovarian Cancer Progression
    DOI: 10.3390/biom15121685
  • 2025

    Journal article

    Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial
    DOI: 10.1038/s41467-025-64130-6

We acknowledge and pay respect to the Traditional Owners of the lands upon which our campuses are situated

Read about our commitment to reconciliation  

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia


View all Campus locations  
facebookIconlinkedinIconinstagramIcontwitterIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy  |  VaxFACTS

CRICOS number: 00116K     ABN: 84 002 705 224